Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Alemtuzumab in Relapsed/Refractory CLL/SLL
NCT00935792Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2009
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Mayo Clinic. Started Jul 2009; status: completed.
02
Drugs
everolimus
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00935792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00935792.